Connection

Co-Authors

This is a "connection" page, showing publications co-authored by SHANNON NEVILLE WESTIN and AMIR A JAZAERI.
Connection Strength

3.067
  1. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.647
  2. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10.
    View in: PubMed
    Score: 0.244
  3. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience. 2024 May 17; 27(5):109801.
    View in: PubMed
    Score: 0.239
  4. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Apr 12; 5(4):311-320.e3.
    View in: PubMed
    Score: 0.237
  5. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
    View in: PubMed
    Score: 0.232
  6. Transforming ovarian cancer care by targeting minimal residual disease. Med. 2023 11 10; 4(11):755-760.
    View in: PubMed
    Score: 0.231
  7. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
    View in: PubMed
    Score: 0.216
  8. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.199
  9. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
    View in: PubMed
    Score: 0.194
  10. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024 Nov; 21(11):781-800.
    View in: PubMed
    Score: 0.061
  11. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res. 2024 Jul 15; 30(14):2986-2995.
    View in: PubMed
    Score: 0.061
  12. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. 2023 07 05; 28(7):618-623.
    View in: PubMed
    Score: 0.056
  13. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer. 2023 06 01; 129(11):1672-1680.
    View in: PubMed
    Score: 0.055
  14. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.
    View in: PubMed
    Score: 0.055
  15. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. 2022 11; 167(2):139-145.
    View in: PubMed
    Score: 0.053
  16. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel). 2022 Jul 23; 14(15).
    View in: PubMed
    Score: 0.053
  17. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.048
  18. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.
    View in: PubMed
    Score: 0.048
  19. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
    View in: PubMed
    Score: 0.047
  20. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575.
    View in: PubMed
    Score: 0.046
  21. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.